A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RE
A phase 3 trial of Ramucirumab, Erlotinib, Gefitinib in non-small-cell lung cancer and small-cell lung cancer, run by Eli Lilly and Company, active and no longer recruiting.
Overview
A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY) is a phase 3 interventional study registered as NCT02411448 by Eli Lilly and Company, with 545 participants enrolled, started 2015-05-06 and due to reach its primary completion in 2019-01-23. Interventions recorded: Ramucirumab, Placebo, Erlotinib, Gefitinib, Osimertinib. Conditions listed: Metastatic Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer
Shares Erlotinib, Eli Lilly (incl. Loxo), Small-cell lung cancer, Non-small-cell lung cancer.
- TrialTo Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic N
Shares Erlotinib, Small-cell lung cancer, Non-small-cell lung cancer.
- TermEGFR exon 19 deletion & L858R
Shares Gefitinib, Erlotinib, Osimertinib, Non-small-cell lung cancer.
- TrialA Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLC
Shares Osimertinib, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialPhase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)
Shares Gefitinib, Osimertinib, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)
Shares Osimertinib, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection
Shares Osimertinib, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialStudy to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm
Shares Osimertinib, Small-cell lung cancer, Non-small-cell lung cancer.